glp 1 market size 2024 GLP-1 Agonists Weight Loss Drugs Report, 2025-2030 The United States GLP-1 Receptor

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

however, this contradicts established trial data favoring SGLT2 inhibitors for heart failure and should be interpreted cautiously due to possible residual confounding

If you are pregnant or lactating, taking medication or have a medical condition, consult your healthcare practitioner before use